Even one fall by an older adult is just as accurate in predicting cognitive decline as individuals with elevated amyloid, the Alzheimer’s brain protein considered the gold standard for gauging Alzheimer’s dementia risk, according to a new study.
Read more HERE
New research reveals the adult brain generates fresh nerve cells in the hippocampus, vital for memory. This ability declines in Alzheimer’s patients. Scientists observed this process in postmortem brain samples. Healthy older adults show continued neuron production.
At the American Glaucoma Society (AGS) 2026 Annual Meeting, Thomas Johnson, MD, PhD, explored the epidemiological and pathophysiological overlaps between glaucoma and Alzheimer’s disease in a talk entitled “The Neurodegeneration Spectrum: Glaucoma and Alzheimer’s Disease.” In it, he highlighted similarities between these two neurodegenerative diseases and explained how insights from each condition could help advance the understanding of the other.
Read more HERE
A team co-led by UCL researchers has reversed Alzheimer’s disease pathology in mice using nanoparticles that help the brain to clear away toxic amyloid proteins naturally.
9 October 2025
A team co-led by UCL researchers has reversed Alzheimer’s disease pathology in mice using nanoparticles that help the brain to clear away toxic amyloid proteins naturally.
Unlike traditional nanomedicine, which relies on nanoparticles as carriers for therapeutic molecules, the approach utilised nanoparticles that are bioactive in their own right, known as “supramolecular drugs”. The work has been published in the journal Signal Transduction and Targeted Therapy.
Instead of targeting neurons directly, the therapy restores the proper function of the blood-brain barrier, the vascular gatekeeper that regulates the brain’s environment. By repairing this critical interface, the researchers achieved a reversal of Alzheimer’s pathology in animals.
The brain obtains its energy from a vast blood supply, supported by a unique and dense vascular system, where a single capillary nourishes each neuron.
Read more HERE
For decades, families affected by Alzheimer’s have had little more than hope to cling to.
Today, however, there are treatments that can slow the progression of early-stage Alzheimer’s. After years of setback and frustration, finally there are medicines that change the trajectory of the disease rather than simply managing symptoms.
We’ve proven that science can address the issue. Now the challenge we face is practical.
In the UK, these new treatments are not available in the NHS. If you want them, you have to pay for them. That’s because of the way the NHS makes decisions about what medicines it will fund – this approach aims to balance the costs to the NHS against the benefits of any treatment. In the case of two new treatments for Alzheimer’s disease neither was judged as “cost effective”.
New treatments pose real challenges for health systems when making these decisions. The data about them is limited – usually just from a clinical trial over a fixed period in group of participants who don’t fully reflect the people who will use the treatment in the health system. It’s no surprise then that the first treatments to slow the progress of Alzheimer’s would pose uncertainties about their longer-term use in the real world.
Read more HERE
In January 2023, neurologists at Beijing’s Xuanwu Hospital of Capital Medical University published a case study that briefly unsettled everything the field thought it knew about Alzheimer’s disease. Two years later, as new treatments and updated diagnostic criteria reshape how the disease is understood, the questions it raised are still unanswered.
He started forgetting things when he was 17. He couldn’t recall what had happened the day before, couldn’t follow what he’d just read, struggled to retain anything new. By 19, the decline had progressed enough that he withdrew from high school. He could still live independently, but something was clearly wrong.
Read the full article HERE